Loading…
Sells physics-based molecular simulation software for drug and materials discovery, and develops its own drug pipeline.
Sells physics-based molecular simulation software for drug and materials discovery, and develops its own drug pipeline.
Software licences, mostly annual and sold to drug and materials researchers, are the steady line. A second line earns collaboration payments and milestones from partners using its methods, while its own drug programmes add uncertain, lumpy income.
Moat: narrow (IP / patents, process know-how, data). Decades of physics-based simulation technology create a technical edge, but the drug pipeline adds binary risk.
Headquarters: New York, New York, United States · Founded: 1990 · Employees: 850
Size Schrodinger (SDGR) is a United States Information Technology company (Packaged Software) with a market value of $2.23B, the 1723rd largest of 3,117 United States companies the cockpit tracks. Shares closed at $29.82 on 6 Nov 2026.
Performance Over six months the shares gained 124.5%, against +9.4% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 8.9% over the last twelve months (peer median +14.3%); the operating margin is -59.2% (peer median 6.5%).
Valuation It trades at 7.4× enterprise value to sales against a peer median of 3.0× (4th most expensive of 21).
Backlog Backlog (remaining performance obligations) was $187M at 30 Sep 2026, up 251% on a year earlier — 0.7 years of trailing revenue. Backlog detail →
Short interest Short interest is 15.8% of the free float (15 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $259M | $256M | $208M | $217M | $181M |
| Revenue growth | — | +23% | -4% | +20% | — |
| Gross profit | $147M | $143M | $132M | $140M | $101M |
| EBITDA | -$148M | -$161M | -$203M | -$172M | -$142M |
| Net income | -$54.3M | -$103M | -$187M | $40.7M | -$149M |
| Free cash flow | -$130M | $12.5M | -$165M | -$2.92M | -$116M |
| Capital expenditure | $3.40M | $1.44M | $7.31M | $13.4M | $8.01M |
| Total debt | $108M | $109M | $118M | $128M | $116M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Schrodinger SDGR | $2.23B | +125% | +9% | -59% | 7.4× | n/a |
| Certara CERT | $1.84B | +91% | +1% | 5% | 4.8× | 40.7% |
| Recursion Pharmaceuticals RXRX | $2.19B | +6% | +56% | -725% | 25.1× | n/a |
| Relay Therapeutics RLAY | $4.08B | +46% | +24% | -2,999% | 308.8× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SDGR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.0% | +5.7% | 6th highest of 21 |
| 6-month return | +124.5% | +9.4% | 2nd highest of 21 |
| Distance from 52-week high | -11.7% | -30.1% | 5th highest of 21 |
| Revenue growth (TTM) | +8.9% | +14.3% | 9th lowest of 21 |
| Operating margin | -59.2% | 6.5% | 2nd lowest of 21 |
| EV / Sales | 7.4× | 3.0× | 4th most expensive of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Schrodinger SDGR | United States | $2.23B | +125% | +9% | -59% | 7.4× | n/a | n/a |
| SeeWay.ai 002405.SZ | China | $2.18B | -32% | +22% | -29% | 3.2× | n/a | n/a |
| Ethos Technologies LIFE | United States | $2.18B | +13% | +112% | -16% | 2.7× | 24.1% | n/a |
| NetScout Systems NTCT | United States | $2.29B | -19% | +6% | 15% | 1.9× | -0.1% | +0.7% |
| Shanghai Suochen Information Technology 688507.SS | China | $2.31B | +97% | +32% | -2% | 26.8× | n/a | n/a |
| DoubleVerify DV | United States | $2.12B | +23% | +7% | 14% | 2.5× | 9.7% | +25.1% |
| Affle 3i AFFLE.NS | India | $2.36B | +6% | +20% | 18% | 6.9× | 33.0% | +39.3% |
| Pitney Bowes PBI | United States | $2.11B | -1% | -4% | 25% | 2.1× | -5.4% | -11.8% |
| Five9 FIVN | United States | $2.10B | +27% | +9% | 6% | 1.9× | 17.9% | +21.4% |
| RAKUS 3923.T | Japan | $2.38B | +24% | +17% | 31% | 5.9× | 15.8% | +31.4% |
| Amplitude AMPL | United States | $2.09B | +161% | +18% | -27% | 5.2× | 36.9% | +27.4% |
| nCino NCNO | United States | $2.40B | +28% | +9% | 9% | 4.3× | 23.9% | +23.8% |
| Embracer EMBRAC-B.ST | Sweden | $2.08B | +37% | -31% | -43% | 1.0× | -9.8% | +12.0% |
| UCloud Technology 688158.SS | China | $2.08B | -34% | +26% | 2% | 6.8× | n/a | n/a |
| ePlus PLUS | United States | $2.40B | +2% | +15% | 7% | 0.8× | 4.3% | +9.5% |
| Zhejiang Digital Culture Technology 600633.SS | China | $2.06B | -15% | +14% | 10% | 4.0× | 15.4% | -2.8% |
| Mobvista Incorporation 1860.HK | Hong Kong | $2.05B | -43% | +26% | 4% | 0.8× | -1.1% | +31.9% |
| Asana ASAN | United States | $2.43B | +60% | +9% | -15% | 2.8× | 10.7% | +28.4% |
| Blackbaud BLKB | United States | $2.43B | +44% | +2% | 21% | 2.6× | -1.6% | +4.3% |
| Guangdong Aofei Data Technology 300738.SZ | China | $2.44B | -34% | +24% | 23% | 9.3× | n/a | n/a |
| Zhejiang Jinke Tom Culture Industry 300459.SZ | China | $2.01B | -9% | -10% | -108% | 16.4× | 43.2% | -12.5% |
Schrodinger reported $187M of remaining performance obligations at 30 Sep 2026, up 251% from a year earlier and down 1% from the previous quarter. That is 0.7 years of trailing revenue already under contract. Book-to-bill last quarter: 0.96.